

Amendments to the Claims:

Please cancel claims 2-5 and 7-23. Claim 6 has been amended. Claims 24-26 have been added. Please note that all claims currently pending and under consideration in the referenced application are shown below. Please enter these claims as amended. This listing of claims will replace all prior versions and listings of claims in the application. Please cancel claims 2-6 and 7-23 without prejudice to the filing of one or more divisional applications including same.

Listing of Claims:

The subject matter claimed is:

1. (Original) The plasmid pWKK-500.

2-5. (Cancelled)

6. (Amended) A plasmid encoding an anti-HIV therapeutic agent comprising a fusion protein, wherein the fusion protein comprises a DP178 peptide as a targeting moiety and a ricin A chain as a polypeptide toxin, wherein the plasmid ~~is a member selected from the group consisting of pWKK 500, pWKK 501, pWKK 502, pWKK 503, pWKK 504, pWKK 505, pWKK 506, pWKK 507, pWKK 508, pWKK 509, pWKK 510, pWKK 511, pWKK 512, pWKK 513, pWKK 514, pWKK 515, pWKK 516, pWKK 517, pWKK 518, pWKK 519, and pWKK 520.~~ has a nucleotide sequence comprising SEQ ID NO:2.

7-23. (Cancelled).

24. (New) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) SEQ ID NO: 2; and

(b) the full complement of SEQ ID NO: 214.

25. (New) An expression vector comprising a polynucleotide of claim 24 operably linked to an expression control sequence.

26. (New) A host cell transformed or transfected with an expression vector according to claim 25.